Impact of vutrisiran on exploratory cardiac parameters in hereditary transthyretin ‐mediated amyloidosis with polyneuropathy

ConclusionsVutrisiran demonstrated evidence of potential benefit on cardiac manifestations in patients with ATTRv amyloidosis with polyneuropathy, with an acceptable safety profile.

Source: European Journal of Heart Failure - February 7, 2024 Category: Cardiology Authors: Pablo Garcia ‐Pavia, Martha Grogan, Parag Kale, John L. Berk, Mathew S. Maurer, Isabel Conceição, Marcelo Di Carli, Scott D. Solomon, Chongshu Chen, Elena Yureneva, John Vest, Julian D. Gillmore Tags: Research Article Source Type: research